Knowledge, Perceptions, Awareness, and Incidence of Cognitive Health Issues among Undergraduates at Risk for Polycystic Ovarian Disease (PCOD)
Main Article Content
Abstract
INTRODUCTION: Polycystic ovarian disorder is the most common endocrine disorder seen in women of reproductive age. Since emotions are largely influenced by hormonal activity, this imbalance in hormone levels can significantly impact mental health. Young women with PCOD can have body image and self-esteem issues due to difficulty in losing weight and excess facial hair growth. Not only that but irregular menstrual cycles and fertility changes can cause them to have chronic high stress levels and anxiety.
MATERIAL & METHOD: An online structured questionnaire was created to collect data from 123 medical UG students of batch 2023 of various medical colleges.
RESULTS: Most participants began menstruating between ages 12 and 14, with a majority tracking their menstrual cycles and being informed about PCOD. While 90% of participants experience dysmenorrhea, only a small proportion take medication regularly for it. The majority sleep 6-8 hours daily, though some report irregular or insufficient sleep, indicating a need for better sleep hygiene. Stress levels are moderate for most, with a significant number experiencing anxiety, particularly related to academic pressures. Dietary habits show a reliance on fast food, with 52% consuming it 2-4 times weekly, which may contribute to weight management difficulties for some participants.
CONCLUSION: These findings suggest the importance of targeted interventions, including stress management, improved sleep hygiene, and healthier eating habits, to enhance the overall well-being and quality of life for young women, particularly concerning reproductive health and academic pressures.
Article Details

This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Sadeghi HM, Adeli I, Calina D, Docea AO, Mousavi T, Daniali M, Nikfar S, Tsatsakis A, Abdollahi M. Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. Int J Mol Sci. 2022 Jan 6;23(2):583.
II. World Health Organization. (2023, June 28). Polycystic ovary syndrome. Retrieved from https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome
III. Dybciak P, Humeniuk E, Raczkiewicz D, Krakowiak J, Wdowiak A, Bojar I. Anxiety and Depression in Women with Polycystic Ovary Syndrome. Medicina (Kaunas). 2022 Jul 16;58(7):942.
IV. Fernandez RC, Moore VM, Van Ryswyk EM, Varcoe TJ, Rodgers RJ, March WA, et al. Sleep disturbances in women with polycystic ovary syndrome: prevalence, pathophysiology, impact, and management strategies. Nat Sci Sleep. 2018 Feb 1;10: 45-64.
V. Sharma M, Khapre M, Saxena V, Kaushal P. Polycystic ovary syndrome among Indian adolescent girls - A systematic review and metanalysis. Nepal J Epidemiol. 2021 Sep 30;11(3):1063-1075.
VI. Bharali MD, Rajendran R, Goswami J, Singal K, Rajendran V. Prevalence of Polycystic Ovarian Syndrome in India: A Systematic Review and Meta-Analysis. Cureus. 2022 Dec 9;14(12):e3235.
VII. Li H, Gibson EA, Jukic AMZ, Baird DD, Wilcox AJ, Curry CL, Fischer-Colbrie T, Onnela JP, Williams MA, Hauser R, Coull BA, Mahalingaiah S. Menstrual cycle length variation by demographic characteristics from the Apple Women's Health Study. NPJ Digit Med. 2023 May 29;6(1):100.
VIII. Bofill Rodriguez M, Dias S, Jordan V, Lethaby A, Lensen SF, Wise MR, Wilkinson J, Brown J, Farquhar C. Interventions for heavy menstrual bleeding; overview of Cochrane reviews and network meta-analysis. Cochrane Database Syst Rev. 2022 May 31;5(5):CD013180.
IX. Situmorang H, Sutanto RL, Tjoa K, Rivaldo R, Adrian M. Prevalence and risk factors of primary dysmenorrhoea among medical students: BMJ Open. 2024 Oct 29;14(10):e086052.
X. Moran LJ, March WA, Whitrow MJ, Giles LC, Davies MJ, Moore VM. Sleep disturbances in a community-based sample of women with polycystic ovary syndrome. Hum Reprod. 2015 Feb;30(2):466-72.
XI. Basu BR, Chowdhury O, Saha SK. Possible Link Between Stress-related Factors and Altered Body Composition in Women with Polycystic Ovarian Syndrome. J Hum Reprod Sci. 2018 Jan-Mar;11(1):10-18.
XII. Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017 May 1;32(5):1075-1091.
XIII. Asik M, Altinbas K, Eroglu M, Karaahmet E, Erbag G, Ertekin H, Sen H. Evaluation of affective temperament and anxiety-depression levels of patients with polycystic ovary syndrome. J Affect Disord. 2015 Oct 1;185:214-8.
XIV. Panidis D, Tziomalos K, Papadakis E, Vosnakis C, Chatzis P, Katsikis I. Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. Endocrine. 2013 Dec;44(3):583-90.